August 2, 2017
Serotonin and Hot Flashes

Hot flashes are one of the most frequently reported symptoms of perimenopause and menopause. Vasomotor symptoms, aka hot flashes and night sweats, occur in more than 75% of North American women during the transition from perimenopause into menopause, and almost all women with induced menopause or premature menopause. Recent research demonstrates that vasomotor symptoms may last anywhere from 6 months to 14 years with an average duration at 7.4 years.

Hot flashes and night sweats are mostly caused by the hormonal changes of menopause, but can also be affected by lifestyle and medications. Diminished levels of estrogen and progesterone have a direct effect on the hypothalamus, the part of the brain responsible for controlling appetite, sleep cycles, sex hormones and body temperature. The drop in hormones confuses the hypothalamus, also referred to as the body’s thermostat, and makes it read “too hot.” The brain responds to this report by telling the heart, blood vessels and nervous system: “Get rid of the heat!” The message is transmitted almost instantly by the nervous system’s chemical messenger, epinephrine, and additional compounds: norepinephrine, prostaglandins and serotonin. The heart pumps faster, the blood vessels in the skin dilate to circulate more blood to radiate off the heat and the sweat glands release sweat to cool the body.

This heat-releasing mechanism is also how the body keeps from overheating in the summer but when the process is triggered instead by a drop in hormones, the brain’s confused response can make women very uncomfortable. Sometimes giving women an appropriate dose of bioidentical estradiol and progesterone can alleviate hot flashes. However, if hormones, especially estrogen, are not an option, there may be other ways of managing these uncomfortable symptoms.

In 2014, the SSRI “Brisdelle” was approved by the FDA for management of hot flashes. In clinical trials, Brisdelle performed better than placebo, reducing the frequency of hot flashes by 57% to 59% in women who had been reporting at least seven hot flashes per day. The dosage studied was 7.5 milligrams, a dose significantly lower than the typical 30 to 40 milligrams used to treat depression. However, the control group in the study (that is, women who received a placebo) also reported a reduction in the frequency of hot flashes: these women reported a reduction of between 40% and 48%. Women experiencing fewer than seven hot flashes per day were not included in this study, raising the question as to whether Brisdelle would be helpful in milder cases.

The use of SSRIs for hot flash relief is interesting in that it illustrates an association between neurotransmitters and vasomotor symptoms. Achieving neurotransmitter balance can be an effective tool in managing many symptoms, including hot flashes and night sweats. Assessing hormone and neurotransmitter imbalances is accurately and simply done with Labrix’ Neurohormone Complete and Complete Plus panels and may be helpful to swiftly developing a successful treatment approach and to restoring quality of life.

References:
  • Avis, PhD et al. Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition. Jama Intern Med. Feb 16, 2015 (Epub ahead of print).
  • FDA News Release: FDA approves the first non-hormonal treatment for hot flashes associated with menopause. www.fda.gov/newsevents/newsroom/pressannouncements/ucm359030.htm Accessibility verified 3/1/17.
  • The North American Menopause Society. http://www.menopause.org/for-women/sexual-health-menopause-online/causes-of-sexual-problems/hot-flashes. Accessibility verified 2/16/15.
Disclaimer:

All information given about health conditions, treatment, products, and dosages are for educational purposes only and do not constitute medical advice.

 
 
 
 

Labrix Core Training

Join the hundreds of practitioners who have attended Labrix live training events and learn more about these exciting opportunities directly from a Labrix attendee and Dr. Jay Mead, Medical Director and co-founder of Labrix.


 
 
Labrix
Core Training

Portland: August 5, 2017
Chicago: October 14, 2017

Seats are available for Labrix Core Training in Portland and Chicago. Registration is just $150 and includes a free Adrenal Function Panel ($100 value) Register today.


Labrix Advanced
Workshop
Las Vegas, NV
February 9-11, 2018

Early Bird Discount
Save $50

Interested in gaining a deeper understanding of how hormone and neurotransmitter imbalances are affecting your patient’s health?Register today for the Labrix Advanced Workshop to lock in your early bird discount price of $229, a savings of $50! Includes a Free NeuroAdrenal Panel (Value $215).

NAEM
Portland, OR
September 9, 2017

Stop by the Labrix booth at the NAEM conference next month, and learn more about Labrix hormone and neurotransmitter testing.


IFM
Dallas, TX
September 11-15, 2017

Labrix will be in Dallas, Texas for the IFM conference next month, where Labrix founders Dr. Jay Mead and Dr. Erin Lommen will be speaking. Stop by the Doctor's Data booth and talk with our National Sales Manager, Heather Cadwallader, and learn more about what's new with Labrix.


ACAM
San Juan, PR
September 14-16, 2017

Labrix founder, Dr. Erin Lommen, will be flying to beautiful San Juan, to speak at the ACAM conference in mid September. Come take in the sunshine and learn more about adrenal health and minimizing inflammation.